DailyStocks Stock Article Search

https://www.zacks.com/commentary/2261192/top-stock-reports-for-danaher-regeneron-pharmaceuticals-palo-alto-networks?cid=CS-ZC-FT-research_daily-2261192 Apr 24, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW). 0

https://www.zacks.com/stock/news/2259366/honeywell-hon-to-report-q1-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2259366 Apr 22, 2024 - Honeywell's (HON) first-quarter results are likely to have benefited from strength across most of its businesses. Weakness in the warehouse automation market might have been a spoilsport. 0

https://www.zacks.com/stock/news/2257937/will-danaher-dhr-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2257937 Apr 18, 2024 - Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. 0

https://www.zacks.com/stock/news/2257902/danaher-dhr-gears-up-to-post-q1-earnings-is-a-beat-likely?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257902 Apr 18, 2024 - Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives. 0

https://www.zacks.com/stock/news/2257699/carlisle-csl-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2257699 Apr 18, 2024 - Carlisle (CSL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2254795/reasons-why-danaher-dhr-should-be-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2254795 Apr 12, 2024 - Danaher (DHR) is set to benefit from strength across its businesses, acquired assets and shareholder-friendly policies. 0

https://www.zacks.com/stock/news/2249455/danaher-dhr-suffers-a-larger-drop-than-the-general-market-key-insights?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2249455 Apr 02, 2024 - In the closing of the recent trading day, Danaher (DHR) stood at $245.94, denoting a -0.75% change from the preceding trading day. 0

https://www.zacks.com/stock/news/2246601/wall-street-analysts-see-danaher-dhr-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2246601 Mar 27, 2024 - According to the average brokerage recommendation (ABR), one should invest in Danaher (DHR). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? 0

https://www.zacks.com/stock/news/2243768/danaher-dhr-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2243768 Mar 20, 2024 - The latest trading day saw Danaher (DHR) settling at $251.68, representing a -0.81% change from its previous close. 0

https://www.zacks.com/stock/news/2240039/danaher-dhr-benefits-from-business-strength-amid-risks?cid=CS-ZC-FT-analyst_blog|zer_report_update-2240039 Mar 13, 2024 - Danaher (DHR) gains from strength in academic and life science research markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology and Diagnostics units is concerning. 0